<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Acute treatment of migraine in children
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Acute treatment of migraine in children
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Acute treatment of migraine in children
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth J Mack, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marc C Patterson, MD, FRACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerry W Swanson, MD, MHPE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 08, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Migraine is the most common acute and recurrent headache syndrome in children. It is characterized by episodes of severe headache often accompanied by nausea, vomiting, photophobia, phonophobia, and abdominal pain and is relieved by sleep.
        </p>
        <p>
         The acute treatment of migraine in children is reviewed here. Other aspects of pediatric migraine are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6202.html" rel="external">
          "Types of migraine and related syndromes in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6161.html" rel="external">
          "Pathophysiology, clinical features, and diagnosis of migraine in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/98355.html" rel="external">
          "Preventive treatment of migraine in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          APPROACH TO TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goals of acute migraine treatment are to obtain consistent, effective relief of migraine symptoms with minimal side effects and to promote a rapid return to normal function, including participation in school and social activities [
         <a href="#rid1">
          1
         </a>
         ]. The management of migraine consists of general measures, acute treatment, and preventive treatment [
         <a href="#rid2">
          2-4
         </a>
         ]. An individual patient may need all three approaches. The management of pediatric migraine headache varies among clinicians. The sections that follow describe one potential approach for different clinical situations.
        </p>
        <p class="headingAnchor" id="H2487041141">
         <span class="h2">
          General measures for all patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         When migraine symptoms develop, the child should rest or sleep in a dark, quiet room with a cool cloth applied to the forehead if possible.
        </p>
        <p>
         Educating the child and caregivers about migraine headache is an important aspect of care. A headache calendar (diary) may identify triggering factors, clarify features of the attacks, and help evaluate the effectiveness of treatment [
         <a href="#rid2">
          2,5
         </a>
         ]. Precipitating factors (eg, stress, poor sleep habits, irregular meals, odors, weather changes, specific foods, menstrual cycles), if identified, should be addressed. A headache diary suitable for children can be used, such as this
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.childrenshospital.org%2Fsites%2Fdefault%2Ffiles%2Fmedia_migration%2F5e066fcf-202f-45f0-b945-f392aa0a61d7.pdf&amp;token=bEJw9b%2BHAZd92vGcjj9gxgsX%2FlOnUXEGTySHZrKm1NARYwfVOPqsl5wWI7O77xBu00cpc%2FhIORPMtyNlwFmlHpuhayj2A2pKCYEAw%2BXmp2k55XHgfVBO6AvHgO%2FlPieLwbyoVmlwio4STkwM5cXWUg%3D%3D&amp;TOPIC_ID=6168" target="_blank">
          example
         </a>
         from Boston Children’s Hospital.
        </p>
        <p class="headingAnchor" id="H1669750033">
         <span class="h2">
          Step-wise selection of medications for most patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early use of medication during the migraine attack, when the headache pain is still mild, is an important principle of acute migraine treatment [
         <a href="#rid2">
          2,4
         </a>
         ]. Medications useful for the acute treatment of migraine range from analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs) and
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          acetaminophen
         </a>
         to triptans and antiemetics. A trial of several medications may be needed to find treatments that are most effective for individual patients. Our suggested hierarchy for selecting and sequencing pharmacologic agents for acute migraine treatment is divided into tiers (1 to 3) and provides choices for treating migraine attacks of increasing severity and/or refractory responsiveness.
        </p>
        <p class="headingAnchor" id="H3819746654">
         <span class="h3">
          Tier 1 (analgesics)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial treatment of migraine attacks in children and adolescents usually involves a simple analgesic and may include an antiemetic. For treatment-naïve children and adolescents with migraine, we suggest initial acute treatment with either
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          acetaminophen
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">
          ibuprofen
         </a>
         . If the patient does not respond to one, the other can be tried.
         <a class="drug drug_pediatric" data-topicid="12630" href="/z/d/drug information/12630.html" rel="external">
          Naproxen
         </a>
         is an alternative.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          Acetaminophen
         </a>
         , 15 mg/kg per dose as an oral solution, melt (oral disintegrating tablet), tablet, or rectal suppository, with a maximum single dose of 1000 mg. This dose may be repeated in two to four hours if symptoms persist but should not exceed three doses in 24 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">
          Ibuprofen
         </a>
         , 10 mg/kg per dose as an oral solution or tablet. This dose may be repeated in four to six hours if needed. No more than four doses should be given in 24 hours (maximum daily dose 40 mg/kg).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12630" href="/z/d/drug information/12630.html" rel="external">
          Naproxen
         </a>
         , 5 mg/kg per dose as an oral solution or tablet. This dose may be repeated in 8 to 12 hours if symptoms persist (maximum daily dose 1000 mg).
        </p>
        <p>
        </p>
        <p>
         To prevent the development of medication overuse headache, analgesics should not be used more than 14 days per month. (See
         <a class="local">
          'Avoiding medication overuse'
         </a>
         below.)
        </p>
        <p>
         Analgesics are reviewed in greater detail below. (See
         <a class="local">
          'Analgesics'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H838582132">
         <span class="h3">
          Tier 2 (triptans)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children at least six years of age who have moderate to severe migraine attacks or who have acute migraine of any severity that is refractory to analgesics, we suggest treatment with a triptan. The choice of triptan, route of administration, and dose depends upon several factors, including the child's age, weight, ability to swallow pills, and whether the migraine attacks are associated with nausea and vomiting. It is reasonable to offer an alternate triptan if one triptan does not provide sufficient relief [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         For children who are unable to swallow pills and for children who have migraine attacks associated with significant nausea and vomiting,
         <a class="drug drug_pediatric" data-topicid="17059" href="/z/d/drug information/17059.html" rel="external">
          rizatriptan
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="108666" href="/z/d/drug information/108666.html" rel="external">
          zolmitriptan
         </a>
         are available as orally disintegrating tablets and/or films, and
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          sumatriptan
         </a>
         and zolmitriptan are available as nasal sprays. A nonoral route of delivery may be preferred for patients when headache pain rapidly reaches maximum severity, is accompanied by nausea or vomiting, or is unresponsive to oral formulations [
         <a href="#rid2">
          2,4
         </a>
         ].
        </p>
        <p>
         Triptan dosing varies by body weight and age.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Older children and adolescents
         </strong>
         – Children who are older than 12 years of age and weigh more than 40 kg often tolerate adult doses of the triptans; options include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="15939" href="/z/d/drug information/15939.html" rel="external">
          Almotriptan
         </a>
         12.5 mg tablet
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="17059" href="/z/d/drug information/17059.html" rel="external">
          Rizatriptan
         </a>
         10 mg tablet or melt (the dose should be decreased in patients taking concomitant
         <a class="drug drug_pediatric" data-topicid="12744" href="/z/d/drug information/12744.html" rel="external">
          propranolol
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="17059" href="/z/d/drug information/17059.html" rel="external">
          Rizatriptan
         </a>
         10 mg oral film
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          Sumatriptan
         </a>
         50 mg tablet
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          Sumatriptan
         </a>
         10 mg nasal spray
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="108666" href="/z/d/drug information/108666.html" rel="external">
          Zolmitriptan
         </a>
         5 mg tablet, melt, or nasal spray
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Younger children
         </strong>
         – Children between 6 and 11 years of age and who weigh less than 40 kg should begin with the smallest available dose of triptan in order to minimize the chance of adverse effects. For children who weigh less than 40 kg (generally 6 to 12 years of age), options include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="15939" href="/z/d/drug information/15939.html" rel="external">
          Almotriptan
         </a>
         6.25 mg oral tablet
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="17059" href="/z/d/drug information/17059.html" rel="external">
          Rizatriptan
         </a>
         5 mg oral tablet (decrease the dose with concomitant
         <a class="drug drug_pediatric" data-topicid="12744" href="/z/d/drug information/12744.html" rel="external">
          propranolol
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          Sumatriptan
         </a>
         25 mg oral tablet
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          Sumatriptan
         </a>
         5 mg nasal spray
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="108666" href="/z/d/drug information/108666.html" rel="external">
          Zolmitriptan
         </a>
         2.5 mg tablet, melt, or nasal spray
        </p>
        <p>
        </p>
        <p>
         To prevent the development of medication overuse headache, triptans should not be used more than nine days per month. (See
         <a class="local">
          'Avoiding medication overuse'
         </a>
         below.)
        </p>
        <p>
         Triptans are reviewed in greater detail below. (See
         <a class="local">
          'Triptans'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H889006474">
         <span class="h3">
          Tier 3 (combination)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children (age ≥6 years) and adolescents who have acute migraine attacks that are refractory to monotherapy with other acute migraine medications, we suggest treatment with a triptan taken together with an analgesic medication (eg, a triptan taken with
         <a class="drug drug_pediatric" data-topicid="12630" href="/z/d/drug information/12630.html" rel="external">
          naproxen
         </a>
         5 mg/kg per dose, or the proprietary combination drug
         <a class="drug drug_pediatric" data-topicid="109842" href="/z/d/drug information/109842.html" rel="external">
          sumatriptan-naproxen
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]. Another option is
         <a class="drug drug_pediatric" data-topicid="12735" href="/z/d/drug information/12735.html" rel="external">
          promethazine
         </a>
         0.25 to 0.5 mg/kg per dose, typically used as adjunct therapy with a triptan or with a triptan plus naproxen. (See
         <a class="local">
          'Combined sumatriptan and naproxen'
         </a>
         below and
         <a class="local">
          'Antiemetics'
         </a>
         below.)
        </p>
        <p>
         The combination drug
         <a class="drug drug_general" data-topicid="9439" href="/z/d/drug information/9439.html" rel="external">
          acetaminophen-isometheptene-dichloralphenazone
         </a>
         was once commonly used to treat migraine for adolescents and children older than eight years of age. However, supporting data are limited to studies in adults [
         <a href="#rid6">
          6-9
         </a>
         ]. This drug is not widely available in all countries.
        </p>
        <p class="headingAnchor" id="H489758930">
         <span class="h2">
          Clinical factors that impact medication selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specific features of the headache may be used to guide medication selection and hasten relief. These include severity and duration of symptoms, the presence of associated nausea and vomiting, and responsiveness to prior medications used. In addition, treatment may vary by setting and patient-level factors such as children at school, those in emergency department settings, and patients who are pregnant.
        </p>
        <p class="headingAnchor" id="H603540740">
         <span class="h3">
          Attack severity
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild attacks
         </strong>
         – Although the distinction is subjective, a mild migraine attack may be considered one that is nondisabling; the child or adolescent can continue to participate in activities without functional impairment. A moderate or severe migraine attack causes some degree of functional impairment that interferes with the ability to fully participate in usual activities at school, home, or outdoors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For migraine attacks with mild pain and minimal disability, over the counter analgesics (NSAIDs,
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          acetaminophen
         </a>
         ) are first-choice agents because they are generally effective, less expensive, and less likely to cause adverse effects than migraine-specific agents such as triptans.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For children and adolescents with acute mild migraine headache, we suggest initial treatment with an analgesic, either
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          acetaminophen
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">
          ibuprofen
         </a>
         , both of which have efficacy for migraine in children in a randomized controlled trial. The choice depends upon individual preference. If the patient does not respond to one, the other can be tried.
         <a class="drug drug_pediatric" data-topicid="12630" href="/z/d/drug information/12630.html" rel="external">
          Naproxen
         </a>
         is an alternative analgesic in this setting.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Variable attacks
         </strong>
         – Many patients with migraine have attacks that vary in severity, time of onset, and association with vomiting and nausea [
         <a href="#rid10">
          10
         </a>
         ]. These patients may require two or more options for the management of acute migraine, including oral medications for mild attacks and nonoral medications (eg, subcutaneous or nasal triptans) for more severe attacks or those associated with vomiting or severe nausea.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe attacks
         </strong>
         – For migraine attacks with moderate to severe headache pain or disability, analgesics may still be effective, and migraine-specific agents (triptans) can be tried if the migraine attack does not respond to simple analgesics.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who present with migraine in emergency settings generally have unusually severe or long-lasting attacks, and in many cases their customary acute migraine treatment has failed to provide relief [
         <a href="#rid11">
          11-13
         </a>
         ]. The treatment of migraine attacks in the emergency department or other urgent care settings follows the same principles as treatment in nonurgent settings outlined above, with the obvious difference that parenteral medications are available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For children who present in emergency or urgent care settings and fail to improve with analgesics, we suggest the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The most effective treatment in our clinical experience is intravenous (IV) fluid therapy, such as 20 mL/kg of normal
         <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">
          saline
         </a>
         , given with IV
         <a class="drug drug_pediatric" data-topicid="12734" href="/z/d/drug information/12734.html" rel="external">
          prochlorperazine
         </a>
         (0.15 mg/kg to a maximum dose of 10 mg) followed by IV
         <a class="drug drug_pediatric" data-topicid="13402" href="/z/d/drug information/13402.html" rel="external">
          ketorolac
         </a>
         (0.5 mg/kg up to a maximum of 30 mg). Pretreatment with
         <a class="drug drug_pediatric" data-topicid="13236" href="/z/d/drug information/13236.html" rel="external">
          diphenhydramine
         </a>
         may prevent potential dystonic reactions associated with prochlorperazine. (See
         <a class="local">
          'Antiemetics'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reasonable alternatives include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          Sumatriptan
         </a>
         3 to 6 mg administered by subcutaneous injection. (See
         <a class="local">
          'Subcutaneous sumatriptan'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="12602" href="/z/d/drug information/12602.html" rel="external">
          Metoclopramide
         </a>
         0.2 mg/kg by IV administration to a maximum dose of 10 mg. (See
         <a class="local">
          'Antiemetics'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="13232" href="/z/d/drug information/13232.html" rel="external">
          Dihydroergotamine
         </a>
         (DHE) 0.5 mg over three minutes by IV administration for children who are &lt;25 kg or age ≤9 years and 1 mg over three minutes for children age ≥10 years. DHE administration should be preceded by the use of an antiemetic 20 minutes before the first DHE dose. (See
         <a class="local">
          'Dihydroergotamine'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Status migrainosus
         </strong>
         – Children presenting with untreated status migrainosus (ie, a debilitating migraine attack lasting for more than 72 hours) can be treated initially with parenteral therapies given for severe attacks of shorter duration such as
         <a class="drug drug_pediatric" data-topicid="12734" href="/z/d/drug information/12734.html" rel="external">
          prochlorperazine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13402" href="/z/d/drug information/13402.html" rel="external">
          ketorolac
         </a>
         , a triptan,
         <a class="drug drug_pediatric" data-topicid="12602" href="/z/d/drug information/12602.html" rel="external">
          metoclopramide
         </a>
         , or DHE. However, many children with prolonged migraine symptoms may be unresponsive to initial parenteral dosing and require further treatment in the inpatient setting.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For most children, we suggest a regimen consisting of repetitive IV DHE [
         <a href="#rid14">
          14
         </a>
         ]. All females of childbearing age should first have a negative pregnancy test. For children age 10 years and older, the dose of DHE is 1 mg IV over three minutes every eight hours, with a maximum of 20 doses. For children &lt;25 kg or age 9 years and younger, the dose is 0.5 mg IV every eight hours. Prior to being treated with DHE, all patients should receive a test dose of DHE (one-half the initial dose appropriate for age and weight) to see if the patient is particularly susceptible to adverse events such as nausea, anxiety, or dyskinesia. Patients should also receive pretreatment with an antiemetic (
         <a class="drug drug_pediatric" data-topicid="12734" href="/z/d/drug information/12734.html" rel="external">
          prochlorperazine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12602" href="/z/d/drug information/12602.html" rel="external">
          metoclopramide
         </a>
         ) 30 minutes prior to each DHE dose for the first three doses, followed by
         <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">
          ondansetron
         </a>
         as needed for remaining doses (to prevent the extrapyramidal side effects that can occur with the antidopaminergic drugs).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alternative options for children who do not respond or have a contraindication to DHE include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Valproate sodium – A retrospective series of 83 children with status migrainosus unresponsive to initial abortive treatments and who received an intravenous valproate sodium infusion reported a favorable response (resolution of pain) in 66 percent [
         <a href="#rid15">
          15
         </a>
         ]. Loading dose in this series was 20 mg/kg followed by continuous infusion at 1 mg/kg per hour to achieve a sustained serum level of 80 to 100 mcg/mL. More than 75 percent of responders improved within 24 hours, after which the intravenous infusion switched to oral extended-release
         <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">
          valproic acid
         </a>
         for preventive therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">
          Valproate
         </a>
         may cause teratogenicity and should be avoided in pregnancy wherever possible. Other common adverse effects include nausea, weight gain, and insulin resistance.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Peripheral nerve block (PNB) – In a retrospective single-center cohort of children with status migrainosus who were unresponsive to initial acute migraine treatments, 77 children were treated in a single session with PNB using
         <a class="drug drug_pediatric" data-topicid="13100" href="/z/d/drug information/13100.html" rel="external">
          bupivacaine
         </a>
         administered to the bilateral occipital, superior orbital, and auriculotemporal nerves [
         <a href="#rid16">
          16
         </a>
         ]. A favorable response (≥50 percent improvement) was reported in 49 percent (38 patients) as well as an additional 40 percent of patients who received PNB after nonresponsiveness to treatment with DHE.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2285607412">
         <span class="h3">
          Patients with associated nausea and vomiting
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early use of an antiemetic may relieve symptoms and facilitate sleep if nausea and vomiting are prominent. For children with acute migraine attacks who have nausea and vomiting, we suggest oral or rectal
         <a class="drug drug_pediatric" data-topicid="12735" href="/z/d/drug information/12735.html" rel="external">
          promethazine
         </a>
         in a single dose of 0.25 to 0.5 mg/kg as needed at intervals of four to six hours, in conjunction with simple or combination analgesics.
        </p>
        <p>
         Oral analgesics and triptan medications may be ineffective because of poor absorption secondary to migraine-induced gastric stasis. Thus, a nonoral route of administration (ie, rectal, nasal spray, or injection) may be better for some children whose migraines present with significant nausea or vomiting.
        </p>
        <p class="headingAnchor" id="H3550786083">
         <span class="h3">
          Special populations
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Young children
         </strong>
         – Early use of medication during the headache episode is an important principle of acute treatment. This may be difficult in young children, who often do not report a migraine until symptoms are severe. The younger the child, the more challenging it is to treat migraine effectively with an acute medication. Therefore, the treatment plan should be straightforward and safe. The parents typically decide when treatment is indicated and when to administer medication.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In general, young children are not able to medicate themselves and often are unable to swallow pills; in such cases, a liquid analgesic preparation is required but may not be tolerated because of nausea and vomiting. For children age 5 years and older, we suggest a trial of
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          sumatriptan
         </a>
         nasal spray due to its proven efficacy in randomized controlled trials in adolescents. In addition, it is generally better tolerated by children than an injection. Sumatriptan nasal spray can be started with a 5 mg dose and repeated once. Older children can use a dose of 20 mg. One drawback to nasal sumatriptan is the associated bad taste, which limits its acceptability in children. This problem can be mitigated by having children suck on a piece of hard candy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Children in school
         </strong>
         – In the school-age child, a school nurse or other professional must administer medicine. The directions from the clinician and parents should include specific guidelines for the school. Often the school requires the parents to sign a permission form to treat.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnant patients
         </strong>
         – The acute treatment of migraine in pregnancy differs somewhat from that in others because of concerns about adverse fetal drug effects. This aspect of acute migraine care is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/4797.html" rel="external">
          "Headache during pregnancy and postpartum", section on 'Acute migraine treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H603540775">
         <span class="h3">
          Avoiding medication overuse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medication overuse headache (MOH), also called analgesic rebound headache, is associated with significant morbidity. Acute symptomatic medications used to treat headaches have the potential for causing MOH. The risk for MOH appears to be highest with opioids, butalbital-containing combination analgesics, and triptans. The risk with triptans is considered intermediate by some experts but high by others. The risk is lowest with NSAIDs. (See
         <a class="medical medical_review" href="/z/d/html/3340.html" rel="external">
          "Medication overuse headache: Etiology, clinical features, and diagnosis", section on 'Causal medications'
         </a>
         .)
        </p>
        <p>
         The risk of MOH is minimized by educating patients and caregivers about this condition and by limiting the use of analgesics (eg,
         <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">
          ibuprofen
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          acetaminophen
         </a>
         ) to no more than 14 days per month and triptans to no more than 9 days per month [
         <a href="#rid2">
          2,4
         </a>
         ]. Any combination of triptans or analgesics should be limited to no more than 9 days per month for no more than three months [
         <a href="#rid2">
          2
         </a>
         ]. Opioids should not be used to treat migraine in children.
        </p>
        <p>
         Families and children should be encouraged to record the frequency and amount of analgesic used in a headache diary (log) or calendar. Preventive therapies should be used as the mainstay in patients with frequent headaches. (See
         <a class="medical medical_review" href="/z/d/html/98355.html" rel="external">
          "Preventive treatment of migraine in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          EFFICACY OF SPECIFIC DRUGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The acute symptomatic therapy of migraine ranges from the use of simple over-the-counter analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs) or
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          acetaminophen
         </a>
         to triptans, antiemetics, or the less commonly used
         <a class="drug drug_pediatric" data-topicid="13232" href="/z/d/drug information/13232.html" rel="external">
          dihydroergotamine
         </a>
         . However, there are limited data from high-quality randomized controlled trials regarding the treatment of migraine in children and adolescents [
         <a href="#rid2">
          2,3
         </a>
         ]. Thus, many management recommendations are additionally based upon experience in adults as well as expert opinion.
        </p>
        <p>
         Medications used for the preventive treatment of pediatric migraine are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/98355.html" rel="external">
          "Preventive treatment of migraine in children", section on 'Pharmacologic treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H603541009">
         <span class="h2">
          Analgesics
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          Acetaminophen
         </a>
         and NSAID often are effective treatment for migraine attacks in children, although supporting evidence is limited [
         <a href="#rid2">
          2,17,18
         </a>
         ]. Early administration of acetaminophen,
         <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">
          ibuprofen
         </a>
         , or other NSAIDs may be helpful.
        </p>
        <p>
         Opioids, barbiturates, and benzodiazepines should not be used to treat headache in children because they are habit-forming and have not been found to be effective [
         <a href="#rid19">
          19,20
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="12829" href="/z/d/drug information/12829.html" rel="external">
          Aspirin
         </a>
         should be used only as a last resort because of concern about Reye syndrome. (See
         <a class="medical medical_review" href="/z/d/html/6154.html" rel="external">
          "Acute toxic-metabolic encephalopathy in children", section on 'Reye syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H823780442">
         <span class="h3">
          Acetaminophen
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a double-blind crossover study of 88 children,
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          acetaminophen
         </a>
         was effective for migraine relief [
         <a href="#rid21">
          21
         </a>
         ]. Acetaminophen (paracetamol) is administered in an initial dose of 15 mg/kg as an oral solution or as one or two 325 mg tablets, with a maximum single dose of 1000 mg. A second dose of 15 mg/kg may be given in two to four hours if symptoms persist. Additional doses may be given at four- to six-hour intervals but should not exceed three doses in 24 hours. Acetaminophen is also available as a melt (oral disintegrating tablet) and rectal suppository.
        </p>
        <p>
         When administered at appropriate doses,
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          acetaminophen
         </a>
         is relatively free of adverse effects [
         <a href="#rid22">
          22,23
         </a>
         ]. Overdose of acetaminophen may cause acute liver failure.
        </p>
        <p class="headingAnchor" id="H114030368">
         <span class="h3">
          Ibuprofen
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a double-blind crossover study of 88 children, aged 4 to 15.8 years, both
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          acetaminophen
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">
          ibuprofen
         </a>
         were effective for migraine relief, but ibuprofen provided faster relief [
         <a href="#rid21">
          21
         </a>
         ]. Three attacks in each child were treated randomly with single oral doses of ibuprofen (10 mg/kg), acetaminophen (15 mg/kg), or placebo. Ibuprofen and acetaminophen were three and two times, respectively, more likely to reduce headache severity than was placebo. The headache was aborted within two hours twice as often with ibuprofen than with acetaminophen.
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">
          Ibuprofen
         </a>
         is given in a dose of 10 mg/kg as an oral solution or tablet. This dose may be repeated in four to six hours if needed. No more than four doses should be given in 24 hours (maximum daily dose 40 mg/kg). Ibuprofen should be used with caution in patients with chronic abdominal pain or tinnitus. Adverse events associated with NSAID use include gastrointestinal bleeding and renal toxicity. (See
         <a class="medical medical_review" href="/z/d/html/7991.html" rel="external">
          "Nonselective NSAIDs: Overview of adverse effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4125321313">
         <span class="h3">
          Others
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Naproxen
         </strong>
         – There are few data for
         <a class="drug drug_pediatric" data-topicid="12630" href="/z/d/drug information/12630.html" rel="external">
          naproxen
         </a>
         in pediatric migraine, but it is effective compared with placebo in the treatment of adults with acute migraine [
         <a href="#rid24">
          24,25
         </a>
         ]. Naproxen, 5 mg/kg per dose, can be given up to three times per day at 8- to 12-hour intervals (maximum daily dose 1000 mg). Naproxen should be used with caution in patients with epigastric pain or worsening nausea. (See
         <a class="medical medical_review" href="/z/d/html/7991.html" rel="external">
          "Nonselective NSAIDs: Overview of adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ketorolac
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13402" href="/z/d/drug information/13402.html" rel="external">
          Ketorolac
         </a>
         by intravenous (IV) administration may also be beneficial for pediatric migraine. A randomized trial comparing
         <a class="drug drug_pediatric" data-topicid="12734" href="/z/d/drug information/12734.html" rel="external">
          prochlorperazine
         </a>
         with ketorolac found that IV ketorolac (0.5 mg/kg, maximum 30 mg) successfully treated migraine within 60 minutes in 55 percent of 29 children, with a 50 percent or greater reduction in the pain score [
         <a href="#rid26">
          26
         </a>
         ]. However, IV prochlorperazine was more effective (with 85 percent of children responding), and the combination of prochlorperazine and ketorolac achieved the highest response rate. (See
         <a class="local">
          'Antiemetics'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Triptans
         </span>
         <span class="headingEndMark">
          —
         </span>
         The triptans represent a significant advance in the abortive treatment of migraine. They are serotonin agonists with an affinity for 5-HT
         <sub>
          1B/1D
         </sub>
         receptors [
         <a href="#rid27">
          27
         </a>
         ]. Triptans are thought to have multiple mechanisms of action. All of the triptans inhibit the release of vasoactive peptides, promote vasoconstriction, and block pain pathways in the brainstem [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         Triptans inhibit transmission in the trigeminal nucleus caudalis, thereby blocking afferent input to second order neurons; this effect is probably mediated by reducing the levels of calcitonin gene-related peptide (CGRP) (see
         <a class="medical medical_review" href="/z/d/html/6161.html" rel="external">
          "Pathophysiology, clinical features, and diagnosis of migraine in children", section on 'Role of CGRP'
         </a>
         ). Triptans may also activate 5-HT
         <sub>
          1B/1D
         </sub>
         receptors in descending brainstem pain-modulating pathways and thereby inhibit dural nociception [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         The US Food and Drug Administration (FDA) has approved the use of
         <a class="drug drug_pediatric" data-topicid="17059" href="/z/d/drug information/17059.html" rel="external">
          rizatriptan
         </a>
         for children 6 to 17 years of age. For children 12 years of age and older, FDA-approved triptans are
         <a class="drug drug_pediatric" data-topicid="15939" href="/z/d/drug information/15939.html" rel="external">
          almotriptan
         </a>
         , rizatriptan (tablet, oral disintegrating tablet or oral film),
         <a class="drug drug_pediatric" data-topicid="108666" href="/z/d/drug information/108666.html" rel="external">
          zolmitriptan
         </a>
         nasal spray, and the combination of
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          sumatriptan
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12630" href="/z/d/drug information/12630.html" rel="external">
          naproxen
         </a>
         . There is published experience with use of other triptans in the pediatric age range as well [
         <a href="#rid2">
          2,4,17,30
         </a>
         ].
        </p>
        <p>
         Triptans are contraindicated in children or adolescents with a history of ischemic vascular disease or arrhythmias associated with accessory conduction pathway disorders [
         <a href="#rid4">
          4
         </a>
         ]. Triptans should be used with extreme caution in migraine with brainstem aura (see
         <a class="medical medical_review" href="/z/d/html/3352.html" rel="external">
          "Migraine with brainstem aura"
         </a>
         ) and in hemiplegic migraine (see
         <a class="medical medical_review" href="/z/d/html/14112.html" rel="external">
          "Hemiplegic migraine"
         </a>
         ) because of theoretical concerns about aggravating symptoms that may be caused by vasospasm.
        </p>
        <p>
         Concerns have also been raised about the development of a serotonin syndrome (see
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         ) in patients who use triptans in combination with a selective serotonin reuptake inhibitor (SSRI) or a selective serotonin-norepinephrine reuptake inhibitor (SNRI) [
         <a href="#rid31">
          31
         </a>
         ]. However, the risk of serotonin syndrome posed by the combined use of a triptan with an SSRI or SNRI appears to be very low [
         <a href="#rid32">
          32,33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H27076669">
         <span class="h3">
          Oral triptans
         </span>
         <span class="headingEndMark">
          —
         </span>
         A placebo-controlled randomized trial of 866 patients showed that oral
         <a class="drug drug_pediatric" data-topicid="15939" href="/z/d/drug information/15939.html" rel="external">
          almotriptan
         </a>
         was beneficial for relieving migraine in adolescents aged 12 to 17 [
         <a href="#rid34">
          34
         </a>
         ]. Pain relief at two hours was greater with the 6.25 mg (72 percent), 12.5 mg (73 percent), and 25 mg doses (68 percent) compared with placebo (55 percent), although no differences were seen in the treatment groups for pain freedom at two hours compared with placebo.
        </p>
        <p>
         A single randomized controlled trial of 267 adolescents failed to show efficacy of
         <a class="drug drug_general" data-topicid="8517" href="/z/d/drug information/8517.html" rel="external">
          eletriptan
         </a>
         40 mg compared with placebo [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Early studies failed to show efficacy of 5 mg
         <a class="drug drug_pediatric" data-topicid="17059" href="/z/d/drug information/17059.html" rel="external">
          rizatriptan
         </a>
         versus placebo in adolescents [
         <a href="#rid36">
          36,37
         </a>
         ]. In a latter two-staged study designed to identify placebo nonresponders, a greater proportion of children ages 6 to 17 years taking 5 or 10 mg rizatriptan were pain free at two hours compared with those allocated to placebo (31 percent versus 22 percent) [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         Data for oral
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          sumatriptan
         </a>
         in adolescent children include one randomized controlled trial of 144 adolescents from Japan [
         <a href="#rid39">
          39
         </a>
         ] and another randomized trial of 23 children from Finland [
         <a href="#rid40">
          40
         </a>
         ]. These trials found no benefit for oral sumatriptan compared with placebo. However, in our clinical experience, oral sumatriptan is effective and useful in some children and adolescents.
        </p>
        <p>
         The initial dose of oral
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          sumatriptan
         </a>
         is 25 to 50 mg given as soon as possible after the onset of migraine headache. The dose should be adjusted on an individual basis to a maximum single dose of 50 mg for younger children and 100 mg for older adolescents. The dose may be repeated after two hours, with a maximum of 200 mg/day.
        </p>
        <p>
         A 2019 guideline from the American Academy of Neurology (AAN) and the American Headache Society (AHS) did not identify any high-quality studies to support the effectiveness of oral
         <a class="drug drug_pediatric" data-topicid="108666" href="/z/d/drug information/108666.html" rel="external">
          zolmitriptan
         </a>
         in children, although there is some positive experience noted in the medical literature [
         <a href="#rid2">
          2,41-43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Nasal triptans
         </span>
         <span class="headingEndMark">
          —
         </span>
         For adolescents with acute migraine,
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          sumatriptan
         </a>
         nasal spray (20 mg) and
         <a class="drug drug_pediatric" data-topicid="108666" href="/z/d/drug information/108666.html" rel="external">
          zolmitriptan
         </a>
         nasal spray (5 mg) are more effective than placebo
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nasal
         </strong>
         <strong>
          sumatriptan
         </strong>
         – Nasal
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          sumatriptan
         </a>
         is given to younger children in an initial dose of 5 mg. If this dose is ineffective, 10 mg can be tried. In adolescents, a dose of up to 20 mg can be given. The bad taste that may accompany use of the nasal spray can by lessened by tilting the head forward during administration and sucking on a flavored lozenge or piece of hard candy [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The 2019 AAN/AHS guideline concluded that
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          sumatriptan
         </a>
         20 mg nasal spray was more likely than placebo to reduce migraine headache pain at one and two hours, but confidence in the evidence was low [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         One trial of 738 adolescents (ages 12 to 17) compared placebo with 5 mg and 20 mg of nasal
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          sumatriptan
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ]. Sumatriptan nasal spray 20 mg provided greater headache relief than placebo at 30 minutes (42 versus 33 percent, respectively) and two hours (68 versus 58 percent) post-dose. Photophobia and phonophobia also improved with the 20 mg nasal sumatriptan. The 5 mg dose was no better than placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In another trial, 653 adolescents (12 to 17 years old) with migraine were randomly assigned to one of three doses (5, 10, or 20 mg) of
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          sumatriptan
         </a>
         nasal spray or placebo [
         <a href="#rid46">
          46
         </a>
         ]. Headache relief (ie, a reduction in pain severity) two hours after the 20 mg dose of sumatriptan occurred more often than with placebo (63 versus 53 percent), approaching significance, while complete relief two hours after the 20 mg dose was significantly greater with sumatriptan (36 versus 25 percent). Treatment also significantly reduced photophobia and phonophobia. Taste disturbance, the most frequently reported adverse event, occurred in 26, 30, 19, and 2 percent of patients treated with 20, 10, and 5 mg sumatriptan and placebo, respectively. No serious adverse events occurred.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a trial that used 10 mg of nasal
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          sumatriptan
         </a>
         for children who weighed 20 to 39 kg and 20 mg nasal sumatriptan for children weighing ≥40 kg, both dosing groups had greater headache relief at one and two hours compared with placebo [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nasal
         </strong>
         <strong>
          zolmitriptan
         </strong>
         – Results from randomized controlled trials suggest that nasal
         <a class="drug drug_pediatric" data-topicid="108666" href="/z/d/drug information/108666.html" rel="external">
          zolmitriptan
         </a>
         is effective for acute treatment of migraine in adolescent children. In one randomized controlled trial of 798 adolescents (ages 12 to 17 years) with migraine, pain-free status at two hours after treatment was greater with zolmitriptan nasal spray 5 mg compared with placebo (30 versus 17 percent; odds ratio [OR] 2.18, 95% CI 1.40-3.39) [
         <a href="#rid48">
          48
         </a>
         ]. Another trial enrolled 248 children (ages 12 to 17 years) with migraine (with or without aura) and employed a novel study design because of an anticipated high placebo response rate [
         <a href="#rid49">
          49
         </a>
         ]. Each migraine attack was treated initially with placebo nasal spray (single blind) when the headache reached moderate or severe intensity. If the migraine intensity remained moderate to severe, patients were then randomly assigned (double blind) to zolmitriptan 5 mg nasal spray or placebo nasal spray. For headache improvement at one hour after treatment, the rate of response was higher for patients assigned to zolmitriptan nasal spray compared with placebo (58 versus 43 percent; OR 1.83, 95% CI 1.14-2.94).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the clinical experience of some experts, patients may find that
         <a class="drug drug_pediatric" data-topicid="108666" href="/z/d/drug information/108666.html" rel="external">
          zolmitriptan
         </a>
         nasal spray has a less objectionable taste than
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          sumatriptan
         </a>
         nasal spray.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Subcutaneous sumatriptan
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two small open-label studies suggest that subcutaneous
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          sumatriptan
         </a>
         may be an effective therapy for migraine [
         <a href="#rid50">
          50,51
         </a>
         ]. In one of these reports, subcutaneous sumatriptan was evaluated in a series of 17 children, 6 to 16 years old, with severe migraine [
         <a href="#rid50">
          50
         </a>
         ]. After a 6 mg dose, headache was relieved within one or two hours in 6 and 5 of 15 patients, respectively. Two smaller children had complete relief two hours after a 3 mg dose. In another study of 50 children, 6 to 18 years old, headache response was 78 percent overall, with 30, 60, and 60 to 120 minute response rates of 26, 46, and 6 percent [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2025975479">
         <span class="h2">
          Combined sumatriptan and naproxen
         </span>
         <span class="headingEndMark">
          —
         </span>
         The combination drug
         <a class="drug drug_pediatric" data-topicid="109842" href="/z/d/drug information/109842.html" rel="external">
          sumatriptan-naproxen
         </a>
         was superior to placebo for the treatment of moderate to severe acute migraine headache in a randomized controlled trial of 490 adolescents (ages 12 to 17 years) [
         <a href="#rid52">
          52
         </a>
         ]. At two hours, adolescents assigned to three different doses of combination sumatriptan-naproxen tablets (10/60 mg, 30/180 mg, and 85/500 mg) had significantly higher pain-free rates (29, 27, and 24 percent, respectively) compared with those assigned to placebo (10 percent). All three doses of combination sumatriptan-naproxen were well tolerated. Efficacy was seen in other placebo-controlled randomized trials as well [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Antiemetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early use of an antiemetic may relieve symptoms and facilitate sleep, particularly if nausea and vomiting are prominent. Rectal administration may be preferable in a patient with nausea and vomiting who cannot easily take an oral medication.
        </p>
        <p>
         The phenothiazines may have additional antimigraine properties, although few studies are available.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Promethazine
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12735" href="/z/d/drug information/12735.html" rel="external">
          Promethazine
         </a>
         is the phenothiazine most commonly used in children because it is effective and has a low incidence of acute extrapyramidal reactions, such as oculogyric crisis. The dose is 0.25 to 0.5 mg/kg per dose orally, intramuscularly, or rectally; it should
         <strong>
          not
         </strong>
         be administered intravenously. Promethazine should
         <strong>
          not
         </strong>
         be given to children who are less than two years old because of the potential for severe and potentially fatal respiratory depression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prochlorperazine
         </strong>
         and
         <strong>
          chlorpromazine
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12734" href="/z/d/drug information/12734.html" rel="external">
          Prochlorperazine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13150" href="/z/d/drug information/13150.html" rel="external">
          chlorpromazine
         </a>
         also are effective, but they are used less commonly in children because of concerns about extrapyramidal reactions, although the frequency of this complication is uncertain [
         <a href="#rid54">
          54
         </a>
         ]. A single randomized trial of 62 children presenting to the emergency department with migraine headaches compared IV
         <a class="drug drug_pediatric" data-topicid="13402" href="/z/d/drug information/13402.html" rel="external">
          ketorolac
         </a>
         with IV prochlorperazine; successful treatment of migraine was defined as a 50 percent or greater reduction in pain score within 60 minutes [
         <a href="#rid26">
          26
         </a>
         ]. Prochlorperazine was significantly more effective than ketorolac in achieving treatment success (85 and 55 percent, respectively) and in decreasing the mean pain score. In a retrospective study of 20 consecutive children seen in the emergency department for severe prolonged migraine, treatment with prochlorperazine (0.15 mg/kg intravenously) reduced pain severity in most patients; after three hours, 60 percent reported no pain [
         <a href="#rid55">
          55
         </a>
         ]. No significant side effects were seen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metoclopramide
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12602" href="/z/d/drug information/12602.html" rel="external">
          Metoclopramide
         </a>
         administered intravenously reduces nausea and vomiting associated with migraine. Its use in children usually is reserved for the emergency department and for protracted migraine [
         <a href="#rid11">
          11,13,56
         </a>
         ]. It commonly is used prior to the administration of
         <a class="drug drug_pediatric" data-topicid="13232" href="/z/d/drug information/13232.html" rel="external">
          dihydroergotamine
         </a>
         (see
         <a class="local">
          'Dihydroergotamine'
         </a>
         below). In one trial, adults with migraine seen in an emergency department were assigned randomly to treatment with metoclopramide with or without
         <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">
          ibuprofen
         </a>
         or placebo [
         <a href="#rid57">
          57
         </a>
         ]. Metoclopramide resulted in significantly better relief of pain and nausea than ibuprofen or placebo. The effect of metoclopramide was similar with or without ibuprofen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Acute dystonic reactions may occur with
         <a class="drug drug_pediatric" data-topicid="12602" href="/z/d/drug information/12602.html" rel="external">
          metoclopramide
         </a>
         [
         <a href="#rid58">
          58,59
         </a>
         ]. This complication is thought to occur more commonly in patients younger than 25 years of age. Thus, metoclopramide should be used with caution. Use of
         <a class="drug drug_pediatric" data-topicid="13236" href="/z/d/drug information/13236.html" rel="external">
          diphenhydramine
         </a>
         can counteract some of these untoward effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ondansetron
         </strong>
         – Limited retrospective data suggest that
         <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">
          ondansetron
         </a>
         is useful for treating children with acute migraine in the emergency department [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H603541402">
         <span class="h2">
          Ergots
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of sublingual, oral, and rectal ergot preparations, alone and in combination with
         <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">
          caffeine
         </a>
         and other analgesics, has been used to treat migraine attacks. However, with the exception of IV
         <a class="drug drug_pediatric" data-topicid="13232" href="/z/d/drug information/13232.html" rel="external">
          dihydroergotamine
         </a>
         (see
         <a class="local">
          'Dihydroergotamine'
         </a>
         below), the triptans have replaced ergots for the acute treatment of migraine in children. The utility of ergots is limited by side effects, especially the potentiation of nausea and vomiting and vasospasm.
        </p>
        <p>
         It is believed that ergot preparations should
         <strong>
          not
         </strong>
         be used to treat migraine with brainstem aura (see
         <a class="medical medical_review" href="/z/d/html/3352.html" rel="external">
          "Migraine with brainstem aura"
         </a>
         ) or hemiplegic migraine (see
         <a class="medical medical_review" href="/z/d/html/14112.html" rel="external">
          "Hemiplegic migraine"
         </a>
         ) since they may theoretically aggravate symptoms caused by vasospasm.
        </p>
        <p>
         Combination drugs consisting of ergot derivatives, barbiturate, and belladonna are
         <strong>
          not
         </strong>
         recommended for children because they are potentially habit forming and predispose to medication overuse headache and the chronification of headache [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Dihydroergotamine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13232" href="/z/d/drug information/13232.html" rel="external">
          Dihydroergotamine
         </a>
         (DHE) is available as a nasal spray and as a solution for IV injection. The IV preparation of DHE often is effective in the treatment of severe migraine [
         <a href="#rid62">
          62
         </a>
         ]. This point is illustrated by findings from a retrospective report that reviewed the inpatient treatment of status migrainosus in 32 children (mean age 15 years) who were treated with IV DHE [
         <a href="#rid63">
          63
         </a>
         ]. At time of discharge (mean length of stay three days), approximately 75 percent of the children were headache free. Treatment was well tolerated; nausea was the most frequent side effect. Dosing as used in this trial is described above. (See
         <a class="local">
          'Attack severity'
         </a>
         above.)
        </p>
        <p>
         In an earlier study, 80 percent of children with migraine without aura who failed outpatient treatment responded to IV DHE plus oral
         <a class="drug drug_pediatric" data-topicid="12602" href="/z/d/drug information/12602.html" rel="external">
          metoclopramide
         </a>
         [
         <a href="#rid64">
          64
         </a>
         ]. Side effects were minimal but can include nausea and, in some patients, a worsening of their headache.
        </p>
        <p>
         The use of IV DHE in children usually is restricted to the treatment of protracted migraine that has not responded to other therapies. It is administered in the emergency department or inpatient setting. (See
         <a class="local">
          'Attack severity'
         </a>
         above.)
        </p>
        <p>
         Common side effects of DHE include nausea and anxiety; dyskinesia occurs infrequently. Patients should be pretreated with antiemetic medication (eg,
         <a class="drug drug_pediatric" data-topicid="12734" href="/z/d/drug information/12734.html" rel="external">
          prochlorperazine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12602" href="/z/d/drug information/12602.html" rel="external">
          metoclopramide
         </a>
         ) 30 minutes prior to each dose of DHE. With extended use of DHE, antidopaminergic drugs should be avoided and alternate antiemetic agents (eg,
         <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">
          ondansetron
         </a>
         ) used instead.
        </p>
        <p class="headingAnchor" id="H111669477">
         <span class="h2">
          Intravenous valproate
         </span>
         <span class="headingEndMark">
          —
         </span>
         The utility of IV
         <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">
          valproate
         </a>
         for the treatment of acute migraine in children is not established, and the existing evidence is limited and retrospective [
         <a href="#rid11">
          11,65,66
         </a>
         ]. As an example, one study evaluated 31 adolescents who were treated with IV valproate (500 to 1000 mg infused at 50 mg/minute) one or more times for acute migraine [
         <a href="#rid65">
          65
         </a>
         ]. Of 48 visits with adequate documentation of pain scores, headache relief considered major (51 to 80 percent pain reduction) or complete (81 to 100 percent pain reduction) was achieved in 47 percent of patients, with no or inadequate relief in 53 percent. The few prospective randomized trials evaluating IV valproate treatment for acute migraine in adults also suggest relatively low efficacy [
         <a href="#rid67">
          67-69
         </a>
         ].
        </p>
        <p>
         The use of
         <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">
          valproic acid
         </a>
         and its derivatives for migraine prophylaxis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/98355.html" rel="external">
          "Preventive treatment of migraine in children", section on 'Valproate'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2669581607">
         <span class="h2">
          CGRP antagonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several oral or intranasal small molecule calcitonin gene-related peptide (CGRP) antagonists are available for the treatment of
         <strong>
          adults
         </strong>
         with migraine who are unresponsive to triptan medications. However, the safety and benefit of these agents in children are uncertain and none of these agents are approved for use in children. In addition, cost may be high and is not typically covered by medical insurance. Several clinical trials assessing the safety and efficacy of these agents in children and adolescents are underway [
         <a href="#rid70">
          70-72
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2148012587">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110285.html" rel="external">
          "Society guideline links: Migraine and other primary headache disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/83061.html" rel="external">
          "Patient education: Migraines in children (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/17166.html" rel="external">
          "Patient education: Headaches in children (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/1179.html" rel="external">
          "Patient education: Headache in children (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General measures for all patients
         </strong>
         – When migraine symptoms develop, have the child rest or sleep in a dark, quiet room. Educating the child and caregivers about migraine headache is an important aspect of care. A headache calendar can help identify triggering factors, clarify features of the attacks, and document response to treatment. Precipitating factors, if identified, should be managed. (See
         <a class="local">
          'General measures for all patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial medication selection
         </strong>
         – Early use of medication during the migraine attack, when the headache pain is still mild, is an important principle of acute migraine treatment. For children and adolescents with treatment-naïve acute migraine attacks, we suggest initial treatment with an analgesic, either
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          acetaminophen
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">
          ibuprofen
         </a>
         , rather than a triptan (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For migraine attacks that do not respond to one analgesic, it is reasonable to switch to another analgesic or, for older children (age ≥5 years), to a triptan. (See
         <a class="local">
          'Tier 1 (analgesics)'
         </a>
         above and
         <a class="local">
          'Acetaminophen'
         </a>
         above and
         <a class="local">
          'Ibuprofen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medication selection for patients with specific clinical features
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mild attacks
         </strong>
         – For children and adolescents with acute mild migraine headache, we suggest initial treatment with an analgesic, either
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          acetaminophen
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">
          ibuprofen
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Attack severity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Severe attacks
         </strong>
         – For children (age ≥5 years) and adolescents in the ambulatory setting who have moderate to severe migraine attacks or who have acute migraine attacks of any severity that are refractory to analgesics, we suggest treatment with a triptan (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For children who are unable to swallow pills or have early nausea or vomiting, we prefer the orally disintegrating formulations of
         <a class="drug drug_pediatric" data-topicid="108666" href="/z/d/drug information/108666.html" rel="external">
          zolmitriptan
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="17059" href="/z/d/drug information/17059.html" rel="external">
          rizatriptan
         </a>
         or nasal spray formulations of
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          sumatriptan
         </a>
         and zolmitriptan. (See
         <a class="local">
          'Attack severity'
         </a>
         above and
         <a class="local">
          'Triptans'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For children who present in emergency or urgent care settings and fail to improve with analgesics, we suggest intravenous (IV) fluid therapy, such as 20 mL/kg of normal
         <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">
          saline
         </a>
         , given with IV
         <a class="drug drug_pediatric" data-topicid="12734" href="/z/d/drug information/12734.html" rel="external">
          prochlorperazine
         </a>
         (0.15 mg/kg to a maximum dose of 10 mg) followed by IV
         <a class="drug drug_pediatric" data-topicid="13402" href="/z/d/drug information/13402.html" rel="external">
          ketorolac
         </a>
         (0.5 mg/kg up to a maximum of 30 mg) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Reasonable alternatives include
         <a class="drug drug_pediatric" data-topicid="12821" href="/z/d/drug information/12821.html" rel="external">
          sumatriptan
         </a>
         3 to 6 mg by subcutaneous injection,
         <a class="drug drug_pediatric" data-topicid="12602" href="/z/d/drug information/12602.html" rel="external">
          metoclopramide
         </a>
         0.2 mg/kg IV to a maximum dose of 10 mg, or
         <a class="drug drug_pediatric" data-topicid="13232" href="/z/d/drug information/13232.html" rel="external">
          dihydroergotamine
         </a>
         0.5 mg IV given over three minutes. (See
         <a class="local">
          'Attack severity'
         </a>
         above and
         <a class="local">
          'Antiemetics'
         </a>
         above and
         <a class="local">
          'Triptans'
         </a>
         above and
         <a class="local">
          'Dihydroergotamine'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Severe nausea and vomiting
         </strong>
         – For children with acute migraine who have nausea and vomiting, we suggest oral or rectal
         <a class="drug drug_pediatric" data-topicid="12735" href="/z/d/drug information/12735.html" rel="external">
          promethazine
         </a>
         in a single dose of 0.25 to 0.5 mg/kg as needed at intervals of four to six hours, in conjunction with analgesic, triptan, or combined acute migraine medication (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Patients with associated nausea and vomiting'
         </a>
         above and
         <a class="local">
          'Antiemetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with refractory headaches
         </strong>
         – For children (age ≥5 years) and adolescents who have acute migraine attacks that are refractory to monotherapy with other analgesics or triptans, we suggest treatment with a triptan taken together with an analgesic medication (eg, a triptan taken with
         <a class="drug drug_pediatric" data-topicid="12630" href="/z/d/drug information/12630.html" rel="external">
          naproxen
         </a>
         , or the proprietary combination drug
         <a class="drug drug_pediatric" data-topicid="109842" href="/z/d/drug information/109842.html" rel="external">
          sumatriptan-naproxen
         </a>
         ) or taken with
         <a class="drug drug_pediatric" data-topicid="12735" href="/z/d/drug information/12735.html" rel="external">
          promethazine
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Tier 3 (combination)'
         </a>
         above and
         <a class="local">
          'Combined sumatriptan and naproxen'
         </a>
         above and
         <a class="local">
          'Antiemetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H907652890">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Robert P Cruse, DO, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Hershey AD. Current approaches to the diagnosis and management of paediatric migraine. Lancet Neurol 2010; 9:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oskoui M, Pringsheim T, Holler-Managan Y, et al. Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2019; 93:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2019; 93:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patniyot I, Qubty W. Short-term Treatment of Migraine in Children and Adolescents. JAMA Pediatr 2020; 174:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metsähonkala L, Sillanpää M, Tuominen J. Headache diary in the diagnosis of childhood migraine. Headache 1997; 37:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan RE. A study of midrin in the symptomatic relief of migraine headache. Headache 1974; 14:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behan PO. Isometheptene compound in the treatment of vascular headache. Practitioner 1978; 221:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           OGDEN HD. Controlled studies of a new agent in vascular headache. Headache 1963; 3:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diamond S. Treatment of migraine with isometheptene, acetaminophen, and dichloralphenazone combination: a double-blind, crossover trial. Headache 1976; 15:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor FR, Kaniecki RG. Symptomatic treatment of migraine: when to use NSAIDs, triptans, or opiates. Curr Treat Options Neurol 2011; 13:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gelfand AA, Goadsby PJ. Treatment of pediatric migraine in the emergency room. Pediatr Neurol 2012; 47:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium. Headache 2012; 52:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bachur RG, Monuteaux MC, Neuman MI. A comparison of acute treatment regimens for migraine in the emergency department. Pediatrics 2015; 135:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theroux LM, Cappa R, Mendoza A, et al. Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children. Headache 2020; 60:1653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zafar MS, Stewart AM, Toupin DN, et al. Continuous Intravenous Valproate as Abortive Therapy for Pediatric Status Migrainosus. Neurologist 2018; 23:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goenka A, Chikkannaiah M, Fonseca LD, Kumar G. Peripheral Nerve Blocks: A Tool for Inpatient Pediatric Status Migrainosus. Pediatr Neurol 2023; 138:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richer L, Billinghurst L, Linsdell MA, et al. Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database Syst Rev 2016; 4:CD005220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeric M, Surjan N, Jelicic Kadic A, et al. Treatment of acute migraine attacks in children with analgesics on the World Health Organization Essential Medicines List: A systematic review and GRADE evidence synthesis. Cephalalgia 2018; 38:1592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masonbrink A, Richardson T, Catley D, et al. Opioid Use to Treat Migraine Headaches in Hospitalized Children and Adolescents. Hosp Pediatr 2020; 10:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caruso A, Lazdowsky L, Rabner J, et al. Butalbital and pediatric headache: stay off the downward path. Headache 2015; 55:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hämäläinen ML, Hoppu K, Valkeila E, Santavuori P. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology 1997; 48:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother 2010; 44:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavonas EJ, Reynolds KM, Dart RC. Therapeutic acetaminophen is not associated with liver injury in children: a systematic review. Pediatrics 2010; 126:e1430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suthisisang CC, Poolsup N, Suksomboon N, et al. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache 2010; 50:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Law S, Derry S, Moore RA. Naproxen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013; :CD009455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brousseau DC, Duffy SJ, Anderson AC, Linakis JG. Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. Ann Emerg Med 2004; 43:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 2002; 59:1084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol 2004; 56:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eiland LS, Hunt MO. The use of triptans for pediatric migraines. Paediatr Drugs 2010; 12:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rolan PE. Drug interactions with triptans : which are clinically significant? CNS Drugs 2012; 26:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans RW. Concomitant triptan and SSRI or SNRI use: what is the risk for serotonin syndrome? Headache 2008; 48:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wenzel RG, Tepper S, Korab WE, Freitag F. Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA's alert warranted? Ann Pharmacother 2008; 42:1692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linder SL, Mathew NT, Cady RK, et al. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache 2008; 48:1326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winner P, Linder SL, Lipton RB, et al. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial. Headache 2007; 47:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winner P, Lewis D, Visser WH, et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache 2002; 42:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visser WH, Winner P, Strohmaier K, et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache 2004; 44:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho TW, Pearlman E, Lewis D, et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Cephalalgia 2012; 32:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujita M, Sato K, Nishioka H, Sakai F. Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study. Cephalalgia 2014; 34:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hämäläinen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults? Neurology 1997; 48:1100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evers S, Rahmann A, Kraemer C, et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology 2006; 67:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linder SL, Dowson AJ. Zolmitriptan provides effective migraine relief in adolescents. Int J Clin Pract 2000; 54:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothner AD, Wasiewski W, Winner P, et al. Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache 2006; 46:101.
          </a>
         </li>
         <li class="breakAll">
          Winner P, Rothner AD. Headaches in Children and Adolescents, BC Decker, Hamilton 2001.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winner P, Rothner AD, Wooten JD, et al. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. Headache 2006; 46:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winner P, Rothner AD, Saper J, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics 2000; 106:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahonen K, Hämäläinen ML, Rantala H, Hoppu K. Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial. Neurology 2004; 62:883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winner P, Farkas V, Štillová H, et al. Efficacy and tolerability of zolmitriptan nasal spray for the treatment of acute migraine in adolescents: Results of a randomized, double-blind, multi-center, parallel-group study (TEENZ). Headache 2016; 56:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis DW, Winner P, Hershey AD, et al. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics 2007; 120:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacDonald JT. Treatment of juvenile migraine with subcutaneous sumatriptan. Headache 1994; 34:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linder SL. Subcutaneous sumatriptan in the clinical setting: the first 50 consecutive patients with acute migraine in a pediatric neurology office practice. Headache 1996; 36:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Derosier FJ, Lewis D, Hershey AD, et al. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics 2012; 129:e1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winner P, Linder S, Hershey AD. Consistency of response to sumatriptan/naproxen sodium in a randomized placebo-controlled, cross-over study for the acute treatment of migraine in adolescence. Headache 2015; 55:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polizos P, Engelhardt DM. Dyskinetic phenomena in children treated with psychotropic medications. Psychopharmacol Bull 1978; 14:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kabbouche MA, Vockell AL, LeCates SL, et al. Tolerability and effectiveness of prochlorperazine for intractable migraine in children. Pediatrics 2001; 107:E62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaar CR, Gerard JM, Nakanishi AK. The Use of a Pediatric Migraine Practice Guideline in an Emergency Department Setting. Pediatr Emerg Care 2016; 32:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis GL, Delaney J, DeHart DA, Owens A. The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med 1993; 22:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leopold NA. Prolonged metoclopramide-induced dyskinetic reaction. Neurology 1984; 34:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cowan AN. Acute dystonic reaction to Maxolon (metoclopramide). Med J Aust 1982; 2:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talai A, Heilbrunn B. Ondansetron for Acute Migraine in the Pediatric Emergency Department. Pediatr Neurol 2020; 103:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008; 48:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986; 36:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kabbouche MA, Powers SW, Segers A, et al. Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. Headache 2009; 49:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linder SL. Treatment of childhood headache with dihydroergotamine mesylate. Headache 1994; 34:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiter PD, Nickisch J, Merritt G. Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine. Headache 2005; 45:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avraham SB, Har-Gil M, Watemberg N. Acute confusional migraine in an adolescent: response to intravenous valproate. Pediatrics 2010; 125:e956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache 2001; 41:976.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanen DA, Miller S, French T, Riffenburgh RH. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med 2003; 41:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leniger T, Pageler L, Stude P, et al. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache 2005; 45:42.
          </a>
         </li>
         <li class="breakAll">
          A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab https://clinicaltrials.gov/ct2/show/NCT04537429 (Accessed on May 05, 2023).
         </li>
         <li class="breakAll">
          Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) https://clinicaltrials.gov/ct2/show/NCT05125302 (Accessed on May 05, 2023).
         </li>
         <li class="breakAll">
          Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine https://clinicaltrials.gov/ct2/show/NCT04743141 (Accessed on May 05, 2023).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6168 Version 46.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20129168" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Current approaches to the diagnosis and management of paediatric migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31413171" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31413170" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32568383" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Short-term Treatment of Migraine in Children and Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9150620" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Headache diary in the diagnosis of childhood migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4599014" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A study of midrin in the symptomatic relief of migraine headache.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/372936" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Isometheptene compound in the treatment of vascular headache.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13939581" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Controlled studies of a new agent in vascular headache.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1107267" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Treatment of migraine with isometheptene, acetaminophen, and dichloralphenazone combination: a double-blind, crossover trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21125432" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Symptomatic treatment of migraine: when to use NSAIDs, triptans, or opiates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22964436" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Treatment of pediatric migraine in the emergency room.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22211870" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Rescue therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25624377" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A comparison of acute treatment regimens for migraine in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32853454" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29494433" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Continuous Intravenous Valproate as Abortive Therapy for Pediatric Status Migrainosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36423569" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Peripheral Nerve Blocks: A Tool for Inpatient Pediatric Status Migrainosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27091010" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Drugs for the acute treatment of migraine in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29034788" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Treatment of acute migraine attacks in children with analgesics on the World Health Organization Essential Medicines List: A systematic review and GRADE evidence synthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32295812" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Opioid Use to Treat Migraine Headaches in Hospitalized Children and Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25532552" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Butalbital and pediatric headache: stay off the downward path.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9008503" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20150507" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21098156" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Therapeutic acetaminophen is not associated with liver injury in children: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20236345" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24142263" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Naproxen with or without an antiemetic for acute migraine headaches in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14747817" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12117355" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Mechanisms of action of the 5-HT1B/1D receptor agonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11152011" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15349864" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21028917" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The use of triptans for pediatric migraines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23018546" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Drug interactions with triptans : which are clinically significant?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18377388" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Concomitant triptan and SSRI or SNRI use: what is the risk for serotonin syndrome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18957623" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA's alert warranted?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18484981" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17445100" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12005275" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15447698" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22711898" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24163282" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9109909" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16775229" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11070573" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Zolmitriptan provides effective migraine relief in adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16412157" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16412157" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16492230" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11061765" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15037686" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27329280" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Efficacy and tolerability of zolmitriptan nasal spray for the treatment of acute migraine in adolescents: Results of a randomized, double-blind, multi-center, parallel-group study (TEENZ).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17671066" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Efficacy of zolmitriptan nasal spray in adolescent migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7843952" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Treatment of juvenile migraine with subcutaneous sumatriptan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8783473" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Subcutaneous sumatriptan in the clinical setting: the first 50 consecutive patients with acute migraine in a pediatric neurology office practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22585767" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25881677" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Consistency of response to sumatriptan/naproxen sodium in a randomized placebo-controlled, cross-over study for the acute treatment of migraine in adolescence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/704766" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Dyskinetic phenomena in children treated with psychotropic medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11335783" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Tolerability and effectiveness of prochlorperazine for intractable migraine in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26359823" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The Use of a Pediatric Migraine Practice Guideline in an Emergency Department Setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8427430" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The efficacy of metoclopramide in the treatment of migraine headache.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6538018" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Prolonged metoclopramide-induced dyskinetic reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7132869" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Acute dystonic reaction to Maxolon (metoclopramide)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32433024" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Ondansetron for Acute Migraine in the Pediatric Emergency Department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18808500" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3520384" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Repetitive intravenous dihydroergotamine as therapy for intractable migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19125879" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Inpatient treatment of status migraine with dihydroergotamine in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7843951" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Treatment of childhood headache with dihydroergotamine mesylate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15985107" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20211950" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Acute confusional migraine in an adolescent: response to intravenous valproate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11903525" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12764341" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15663612" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
